{"ticker": {"uuid": "ec910d4c-5980-4fcb-aa91-1f7827f8b5d9", "symbol": "CMMB", "name": "Chemomab Therapeutics Ltd DRC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Chemomab Therapeutics (CMMB) Q3 2025 earnings summary", "summary": "Chemomab Therapeutics (CMMB) reported its Q3 2025 earnings, highlighting advanced preparations for its nebokitug Phase 3 trial in primary sclerosing cholangitis (PSC) with regulatory alignment from the FDA and EMA. The company's cash reserves are expected to fund operations throu", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-q3-2025_F6V0wZFD", "source_name": "Quartr", "published_at": "2026-07-21T05:42:22", "published_display": "21 Jul 2026 05:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Q4 2025 earnings summary", "summary": "Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced ", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-q4-2025_F6V0wJZm", "source_name": "Quartr", "published_at": "2026-07-20T05:42:22", "published_display": "20 Jul 2026 05:42", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Q1 2026 earnings summary", "summary": "Chemomab Therapeutics (CMMB) reported its Q1 2026 earnings, highlighting new clinical data supporting nebokitug's potential as a disease-modifying drug for PSC and IBD, and ongoing partnering discussions. The company's cash reserves of $8.0 million are expected to fund operations", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-q1-2026_F6V0b5xi", "source_name": "Quartr", "published_at": "2026-07-19T02:40:47", "published_display": "19 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) H.C. Wainwright 27th Annual Global Investment Conference summary", "summary": "Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to F", "url": "https://quartr.com/events/chemomab-therapeutics-ltd-cmmb-h-c-wainwright-27th-annual-global-investment-conference_F6V0wIBw", "source_name": "Quartr", "published_at": "2026-07-18T21:40:25", "published_display": "18 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary", "summary": "Chemomab Therapeutics (CMMB) presented a summary of their Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025. Key highlights include positive Phase II results for CM-101 (Nebokitug) in primary sclerosing cholangitis (PSC), with an FDA regulatory path and additional ", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-oppenheimer-35th-annual-healthcare-life-sciences-conference-2025_F6V0wetH", "source_name": "Quartr", "published_at": "2026-07-16T22:41:41", "published_display": "16 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger plan", "summary": "HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which in", "url": "https://www.stocktitan.net/sec-filings/CMMB/schedule-13d-chemomab-therapeutics-ltd-major-shareholder-acquisition--1c2122749b03.html", "source_name": "Stock Titan", "published_at": "2026-07-16T19:41:41", "published_display": "16 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $5", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQMGozOXR4MWxDTFNMMlpWd19GbXRZb2xQY25GZVNRQkJJSFh5MVZKNUVqNlpMSndiWTJ0di1qLTl6S3N3YzhqQ29hMHBlUElTWGpTdG5qYmlmZDQ1d2xDcmYtVHlENUgwcFFGUlFlYXVqTXRzUEw2RnRLeEtpeHpqaEFkbzd6Z0FyQ0ZtQndiMm03c1ZCY2lfNEMyQTVKZ2lMM2p3S3JCZ20tNnB6U3VjZkw4bG82SkZ2N0E?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T16:31:00+00:00", "published_display": "14 Jul 2026 16:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Chemomab Therapeutics (CMMB) Slides 4.9% as Stock Approaches Key Support Zone - Pullback Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQZXFVcXNUU3dNdDJlYjhwcHRhMHVJZEJCb2l1bU1uckdKa2xxbmgxOTZtb214TnpNTXN0YUk0SkJ4OUVNT2RhcVZ0VWh1RjFSSng4WGJ4V0xYdzA4U1ZzU1J1Q1dLNXhRbk9LQlhXeURVRUR5bEZpVjFHYmFLYVZIaUk3b2VEVHltVXlZeE93UnNGcEp1YkhURUw2RDcwRnBzR2hpa0VxQTcwRlNxcjFoT3pwY2Nud2FYYVE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T17:42:48+00:00", "published_display": "11 Jul 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics, Scipher Medicine to Merge in All-Stock Deal", "summary": "Chemomab Therapeutics and Scipher Medicine have announced an all-stock merger, aiming to create a combined company focused on precision immunology. The deal is expected to close in the second half of 2026, with Scipher Medicine shareholders owning approximately 80% of the new ent", "url": "https://www.moomoo.com/news/post/72651881/chemomab-therapeutics-scipher-medicine-to-merge-in-all-stock-deal", "source_name": "Moomoo", "published_at": "2026-07-09T15:12:06", "published_display": "09 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxON2VZNjJJUDBFWUJWQlNkSE12a2RXbnYxNjBhNmxtVnAwVDhHbTRfaGlZTHRZOElDWXRockJwRVBiZXE4SUtDRnFpUEpZeE1kWGVWcG03R3NHN2dMQlJFTWtsR2NwREFyVUxLWENmeTBsMTQtNFdJZWtWeVkyRjVZMlhFWVRFdGk3YzZuODRmTFJJakJ3NFYwZFBnVjJZT01kUUs0aDh4ZW9ndDF0R25mMndwcjJJSUFra2J3Nw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to the merger agreement reached by both parties, upon completion of the transaction, existing shareholders of Chemomab Therapeutics Ltd. are expected to own approximately 32% of the merged new company.", "summary": "In a recent merger agreement, shareholders of Chemomab Therapeutics Ltd. are projected to own about 32% of the newly formed company. Conversely, existing shareholders of Scipher Medicine are expected to hold approximately 68% of the shares, clearly defining the equity distributio", "url": "https://www.bitget.com/amp/news/detail/12560605495728", "source_name": "Bitget", "published_at": "2026-07-09T03:41:36", "published_display": "09 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics Ltd. (CMMB) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This NASDAQ page provides live stock quotes and charts for Chemomab Therapeutics Ltd. (CMMB). It shows the current stock price and highlights that there are no analyst ratings or earnings information currently available for the company. The page also includes various resources re", "url": "https://www.timothysykes.com/quote/CMMB/", "source_name": "www.timothysykes.com", "published_at": "2026-07-09T00:41:36", "published_display": "09 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab, Scipher Bet On Taking AI-Powered Precision Medicine Into Immunology", "summary": "Chemomab and Scipher are merging to combine their expertise in AI and precision medicine for applications in immunology. This strategic move aims to leverage advanced technologies to revolutionize the treatment of immune disorders. The collaboration seeks to enhance drug developm", "url": "https://insights.citeline.com/scrip/digital-technologies/ai/chemomab-scipher-bet-on-taking-ai-powered-precision-medicine-into-immunology-ENV3VV7GKNFXZMOPIYN5SMMB6I/", "source_name": "Scrip", "published_at": "2026-07-08T20:40:18", "published_display": "08 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) M&A announcement Summary", "summary": "Chemomab Therapeutics announced a merger with Scipher, combining AI-powered precision medicine with Chemomab's anti-CCL24 antibody to target rheumatoid arthritis. The all-stock transaction will result in Chemomab shareholders owning approximately 32% of the combined company, with", "url": "https://quartr.com/events/chemomab-therapeutics-ltd-cmmb-m-a-announcement_F6V0bb8M", "source_name": "Quartr", "published_at": "2026-07-08T18:40:18", "published_display": "08 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab and Scipher Medicine agree biotechnology merger", "summary": "Chemomab Therapeutics and Scipher Medicine have announced a stock-based merger, forming Scipher Medicine Corporation, which will focus on advancing nebokitug, an anti-CCL24 antibody, into an AI-guided Phase 2 rheumatoid arthritis trial. The combined company is valued at approxima", "url": "https://grafa.com/en/news/united-states/chemomab-scipher-medicine-merger-nebokitug-rheumatoid-arthritis", "source_name": "grafa.com", "published_at": "2026-07-08T16:40:18", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB Stock Surges As Traders Target Biotech Momentum", "summary": "Shares of Chemomab Therapeutics Ltd. (CMMB) have recently seen significant price action, surging from around $1.50 to the high $2s, demonstrating classic low-float breakout behavior despite recent clinical trial uncertainty. The company's strong cash position relative to liabilit", "url": "https://www.timothysykes.com/news/chemomab-therapeutics-ltd-cmmb-news-2026_07_08/", "source_name": "www.timothysykes.com", "published_at": "2026-07-08T13:40:18", "published_display": "08 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scipher Medicine Corporation entered into an Agreement and Plan of Merger to acquire Chemomab Therapeutics Ltd. with an enterprise value of approximately $100 million in a reverse merger transaction.", "summary": "Scipher Medicine Corporation has formally agreed to acquire Chemomab Therapeutics Ltd. in a reverse merger transaction with an enterprise value of approximately $100 million. The combined entity is valued at $150 million and will be named Scipher Medicine Corporation, trading und", "url": "https://www.marketscreener.com/news/scipher-medicine-corporation-entered-into-an-agreement-and-plan-of-merger-to-acquire-chemomab-therap-ce7f5ed9d188f720?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T13:39:24", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab and Scipher Medicine to merge in $150M deal By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQalJwS25KamtzOVJjaVRMSjhyZlE5cHZvNGxKaHJmQ3VKSTRUYWQxOXB4blFNRXM4Mm93dDdGdjVzVHlEdE1RdVBEQUg1aGYzVTAxZE0zSWduMTYwbVBBSUtqbTQ1U2NRMHdVSi1KdVozcjhadjJxUVZKVTFQVkxzd200ekRiVzRYSjNIbVFydUZrVkk5WGxHeUJwTVV5ajZwWDMyb2NpLXl6elpFSGNEeGdR?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-08T11:48:05+00:00", "published_display": "08 Jul 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab and Scipher Medicine to merge in $150M deal", "summary": "Chemomab Therapeutics and Scipher Medicine Corporation have announced an all-stock merger valued at $150 million, with Chemomab equity holders owning 32% and Scipher 68% of the combined company, which will operate as Scipher Medicine Corporation and trade on Nasdaq as SCIP. The d", "url": "https://www.investing.com/news/company-news/chemomab-and-scipher-medicine-to-merge-in-150m-deal-93CH-4781411", "source_name": "Investing.com", "published_at": "2026-07-08T12:34:45", "published_display": "08 Jul 2026 12:34", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis", "summary": "Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement to combine companies and advance nebokitug, a first-in-class anti-CCL24 antibody, into a precision medicine Phase 2 trial for rheumatoid arthritis. The combined entity, to be named Scipher Med", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323986/0/en/chemomab-therapeutics-and-precision-medicine-pioneer-scipher-medicine-announce-merger-agreement-to-advance-nebokitug-in-an-ai-powered-phase-2-trial-in-rheumatoid-arthritis.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:40:18", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab (CMMB) and Scipher plan merger with $30M financing and CVRs", "summary": "Chemomab Therapeutics and Scipher Medicine announced a definitive merger agreement, creating a new Nasdaq-listed U.S. parent company focused on advancing nebokitug for rheumatoid arthritis (RA) into an AI-enabled Phase 2 trial. The deal involves a $30 million PIPE financing and c", "url": "https://www.stocktitan.net/sec-filings/CMMB/6-k-chemomab-therapeutics-ltd-current-report-foreign-issuer-6909211c1a08.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:11:45", "published_display": "08 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics and Precision Medicine Pioneer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AJBVV95cUxQRGZXX2pvcHJNdjROSVBJUG4xSTZXbmM4N3ZmVGdaWVRvMHVfYmc2VjNxS1B3ZkdfZU04elBtT3VTRC1HZmktclN0SktacFc3dFg2UGh2UWxFT21nVFlqOTU2QkJXaFRBSU1KcFNkLW5ERnVIUUFwQlgtb2RNMElraFJaMzFTTzZDVk5fWF90cDQ0ZVQ0QTRMTWN6eG5RSGw2WmphTTR1QmRKNURJV0kxem9XMmE5M2hMVGZwRWRqRE1yX0NoVWVZS05UQV9JaWxTN29UMlBkaDY5ZWhOUnhEX0sxUkdnek5vWFJQd0c2MlRFZko0U1FEODk0NFZFbTJDa29xb1ZscmZnYWNiY1ktRmVMdGVBcXpQZkpUX0hKdzFocDJBS3RZTEdlQ3Vta3Vscy1BMWJfYWdIRGxvOEg1ZXhFMmd6U3F6NTN0VG5PR3RiZEIxTFdIWEtQY1VJLXdW?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQTWpDYU1LTHlPY083Y1RPX1VQbVZfSGo0OGNhZW5xQk90XzhIeXZBRkpjMFpxWFlsN2d6SUVyeW44aEx1VWZuU2hWWUx1WFdicE5Oa1pmdlVBTDBlekQ1aXdKcnVfNmtwMGE0OGNiTmNMQW9MWDA2LUE2bkF6WGVMSjZlLVBZY0lDZkRMaEY4ZVVJdkNGSVd0eEZGaC14d3NoZ2labjZ6bGpPRW01dFlrSlZFTWNfUVJ6V0ZQNVJic1E2LURrZVNDRE1aWjM4Tk9Oem5HOGRUcENQQlg5WXpFU21sbVlMTWxzLWpWVjRWNy1yLXR2YXd3?oc=5", "source_name": "Moomoo", "published_at": "2026-07-07T21:47:13+00:00", "published_display": "07 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Volatility & Greeks", "summary": "This article provides a detailed financial overview of Chemomab Therapeutics Ltd ADR (CMMB), including its volatility, key financial metrics, stock performance, and insider/institutional ownership. It highlights the company's market capitalization, sales, earnings per share, and ", "url": "https://finviz.com/stock?t=CMMB&ta=1&p=m&ty=ocv&b=1&e=2026-07-04", "source_name": "Finviz", "published_at": "2026-07-05T00:40:35", "published_display": "05 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Earnings", "summary": "This page provides a detailed financial overview of Chemomab Therapeutics Ltd ADR (CMMB), including its latest stock performance, market capitalization, income statements, key financial ratios, and analyst recommendations. The data indicates significant recent stock volatility an", "url": "https://finviz.com/quote?t=CMMB&ty=ea&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T17:09:41", "published_display": "04 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Short Interest", "summary": "This article provides detailed financial data and performance metrics for Chemomab Therapeutics Ltd ADR (CMMB), including its short interest, market capitalization, income, sales, and employee count. It also lists various financial ratios, insider ownership, institutional ownersh", "url": "https://finviz.com/stock?t=CMMB&ta=1&p=m&ty=si&b=1", "source_name": "Finviz", "published_at": "2026-07-04T12:09:41", "published_display": "04 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Chemomab Therapeutics Ltd ADR (CMMB). It details the company's last close price, various financial ratios, performance metrics, and insider/institutional ownership percentages. Key financial figures", "url": "https://finviz.com/stock?t=CMMB&ty=lf&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T15:39:55", "published_display": "03 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Options", "summary": "This article provides a detailed financial overview of Chemomab Therapeutics Ltd. (CMMB), an ADR-listed biotechnology company. It covers key financial metrics, stock performance data, insider and institutional ownership, and analyst recommendations. The company's stock closed at ", "url": "https://finviz.com/stock?t=CMMB&p=d&b=1&ty=oc", "source_name": "Finviz", "published_at": "2026-07-03T11:39:55", "published_display": "03 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "11 Health Care Stocks Moving In Thursday's Intraday Session", "summary": "This article lists several healthcare stocks that experienced significant price movements during Thursday's intraday trading session. It highlights both gainers, such as Chemomab Therapeutics and Liminatus Pharma, and decliners, including Elicio Therapeutics and Profusa, detailin", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60253293/11-health-care-stocks-moving-thursday-s-intraday-session", "source_name": "Benzinga", "published_at": "2026-07-02T17:09:35", "published_display": "02 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the forecast and price target for Chemomab Therapeutics Ltd. (CMMB) on the Nasdaq Stock Market. One analyst currently offers a 1-year price forecast, with a price target of 5.00, although maximum and minimum estimates are not provided. The article also touch", "url": "https://www.tradingview.com/symbols/NASDAQ-CMMB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T02:39:34", "published_display": "29 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Edges Higher as Stock Holds Key Support - Pre-Earnings Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNc2JTbWwtRXlXbnQtMW5YcVFhbHNleHcySkNXaWJIbWRDcE5IZFhLdERZeW9WM0p3bEtMcnhGaGZ2TXJEd0lsM0JqQ3dPU3A2a1d0SDhYNDBPYVlBRW9kb1hWczM4MjFaa2NuaEdBYnBmY1VCZlF6VlIxVG1scUdsTGRZenJpZTF6dDVVYm5YWnR3MUJQdTd4YXJDLUg2NVMzZUVWekp5RQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-28T23:48:46+00:00", "published_display": "28 Jun 2026 23:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Chemomab Therapeutics Ltd. \u2013 NASDAQ:CMMB", "summary": "The article provides the \"Enterprise value to revenue forward\" for Chemomab Therapeutics Ltd. (NASDAQ: CMMB). It is presented on the TradingView platform, which offers financial data, charting tools, and community features for various markets including stocks, ETFs, and cryptocur", "url": "https://www.tradingview.com/symbols/NASDAQ-CMMB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:10:18", "published_display": "28 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Chemomab Therapeutics Ltd. Sponsored ADR \u2013 MUN:2QV", "summary": "This article provides financial information for Chemomab Therapeutics Ltd. Sponsored ADR (MUN:2QV), specifically focusing on its forward price-to-earnings ratio. It indicates that the current market for this stock is closed and no trades have occurred. The data is sourced from IC", "url": "https://www.tradingview.com/symbols/MUN-2QV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:18", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQRGFodkhobHN4MGdlVVpEQXFSbGlFZE5hRndHcTFadE53TkRZdC1FVmpzLVdhdmhzWmlZQnVieGczUVdXenZyWWdvU0YwcUhReWFGcmtBNXh3QllHaW5XUnFBcHlGTC1RU1NqVEhBTERjY1NaRk5zRU1rMGFzVks1LUx6WWx2SVh1dnpjTjlLVy00Ri00emZFVWpOc0dQQjNHaGUya2Z6Sk1nNWRKQmExTE9pWlVMQVlRdV82bk9SWWNmejBhRnU3WnFEajdwaTJIeDlLRmdFejZxakxEQXp2UXFVazBqZTRsMWliNkdLWGljZ2Y4SUthb0Ryc3BLTVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Chemomab Therapeutics (CMMB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1YVEFWNUktd1dVTHJ5SGpVTGp0VFdtelh4WTBQeXlwMVh2REpmOGJMZlAtYUdrbWo0czVHNGpMRERrR3lxSzZCUm0zVDFla2ZSaFV3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:23:46+00:00", "published_display": "24 Apr 2025 23:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB: Chemomab Therapeutics Ltd - ADR Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFBVLUJjenRwT2hHMUlNNkV0YWZsNjBfZlF3WkJIZUdGM245YVRPQ3h4TlM1Nk84X0FsN3hXSnpnM3RKTTd1bC1NeUFn?oc=5", "source_name": "Stocktwits", "published_at": "2021-04-04T01:51:28+00:00", "published_display": "04 Apr 2021 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Chemomab Therapeutics (CMMB) Q3 2025 earnings summary", "summary": "Chemomab Therapeutics (CMMB) reported its Q3 2025 earnings, highlighting advanced preparations for its nebokitug Phase 3 trial in primary sclerosing cholangitis (PSC) with regulatory alignment from the FDA and EMA. The company's cash reserves are expected to fund operations throu", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-q3-2025_F6V0wZFD", "source_name": "Quartr", "published_at": "2026-07-21T05:42:22", "published_display": "21 Jul 2026 05:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Q4 2025 earnings summary", "summary": "Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced ", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-q4-2025_F6V0wJZm", "source_name": "Quartr", "published_at": "2026-07-20T05:42:22", "published_display": "20 Jul 2026 05:42", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Q1 2026 earnings summary", "summary": "Chemomab Therapeutics (CMMB) reported its Q1 2026 earnings, highlighting new clinical data supporting nebokitug's potential as a disease-modifying drug for PSC and IBD, and ongoing partnering discussions. The company's cash reserves of $8.0 million are expected to fund operations", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-q1-2026_F6V0b5xi", "source_name": "Quartr", "published_at": "2026-07-19T02:40:47", "published_display": "19 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) H.C. Wainwright 27th Annual Global Investment Conference summary", "summary": "Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to F", "url": "https://quartr.com/events/chemomab-therapeutics-ltd-cmmb-h-c-wainwright-27th-annual-global-investment-conference_F6V0wIBw", "source_name": "Quartr", "published_at": "2026-07-18T21:40:25", "published_display": "18 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary", "summary": "Chemomab Therapeutics (CMMB) presented a summary of their Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025. Key highlights include positive Phase II results for CM-101 (Nebokitug) in primary sclerosing cholangitis (PSC), with an FDA regulatory path and additional ", "url": "https://quartr.com/events/chemomab-therapeutics-cmmb-oppenheimer-35th-annual-healthcare-life-sciences-conference-2025_F6V0wetH", "source_name": "Quartr", "published_at": "2026-07-16T22:41:41", "published_display": "16 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger plan", "summary": "HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which in", "url": "https://www.stocktitan.net/sec-filings/CMMB/schedule-13d-chemomab-therapeutics-ltd-major-shareholder-acquisition--1c2122749b03.html", "source_name": "Stock Titan", "published_at": "2026-07-16T19:41:41", "published_display": "16 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $5", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQMGozOXR4MWxDTFNMMlpWd19GbXRZb2xQY25GZVNRQkJJSFh5MVZKNUVqNlpMSndiWTJ0di1qLTl6S3N3YzhqQ29hMHBlUElTWGpTdG5qYmlmZDQ1d2xDcmYtVHlENUgwcFFGUlFlYXVqTXRzUEw2RnRLeEtpeHpqaEFkbzd6Z0FyQ0ZtQndiMm03c1ZCY2lfNEMyQTVKZ2lMM2p3S3JCZ20tNnB6U3VjZkw4bG82SkZ2N0E?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T16:31:00+00:00", "published_display": "14 Jul 2026 16:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Slides 4.9% as Stock Approaches Key Support Zone - Pullback Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQZXFVcXNUU3dNdDJlYjhwcHRhMHVJZEJCb2l1bU1uckdKa2xxbmgxOTZtb214TnpNTXN0YUk0SkJ4OUVNT2RhcVZ0VWh1RjFSSng4WGJ4V0xYdzA4U1ZzU1J1Q1dLNXhRbk9LQlhXeURVRUR5bEZpVjFHYmFLYVZIaUk3b2VEVHltVXlZeE93UnNGcEp1YkhURUw2RDcwRnBzR2hpa0VxQTcwRlNxcjFoT3pwY2Nud2FYYVE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T17:42:48+00:00", "published_display": "11 Jul 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics, Scipher Medicine to Merge in All-Stock Deal", "summary": "Chemomab Therapeutics and Scipher Medicine have announced an all-stock merger, aiming to create a combined company focused on precision immunology. The deal is expected to close in the second half of 2026, with Scipher Medicine shareholders owning approximately 80% of the new ent", "url": "https://www.moomoo.com/news/post/72651881/chemomab-therapeutics-scipher-medicine-to-merge-in-all-stock-deal", "source_name": "Moomoo", "published_at": "2026-07-09T15:12:06", "published_display": "09 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxON2VZNjJJUDBFWUJWQlNkSE12a2RXbnYxNjBhNmxtVnAwVDhHbTRfaGlZTHRZOElDWXRockJwRVBiZXE4SUtDRnFpUEpZeE1kWGVWcG03R3NHN2dMQlJFTWtsR2NwREFyVUxLWENmeTBsMTQtNFdJZWtWeVkyRjVZMlhFWVRFdGk3YzZuODRmTFJJakJ3NFYwZFBnVjJZT01kUUs0aDh4ZW9ndDF0R25mMndwcjJJSUFra2J3Nw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to the merger agreement reached by both parties, upon completion of the transaction, existing shareholders of Chemomab Therapeutics Ltd. are expected to own approximately 32% of the merged new company.", "summary": "In a recent merger agreement, shareholders of Chemomab Therapeutics Ltd. are projected to own about 32% of the newly formed company. Conversely, existing shareholders of Scipher Medicine are expected to hold approximately 68% of the shares, clearly defining the equity distributio", "url": "https://www.bitget.com/amp/news/detail/12560605495728", "source_name": "Bitget", "published_at": "2026-07-09T03:41:36", "published_display": "09 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics Ltd. (CMMB) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This NASDAQ page provides live stock quotes and charts for Chemomab Therapeutics Ltd. (CMMB). It shows the current stock price and highlights that there are no analyst ratings or earnings information currently available for the company. The page also includes various resources re", "url": "https://www.timothysykes.com/quote/CMMB/", "source_name": "www.timothysykes.com", "published_at": "2026-07-09T00:41:36", "published_display": "09 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab, Scipher Bet On Taking AI-Powered Precision Medicine Into Immunology", "summary": "Chemomab and Scipher are merging to combine their expertise in AI and precision medicine for applications in immunology. This strategic move aims to leverage advanced technologies to revolutionize the treatment of immune disorders. The collaboration seeks to enhance drug developm", "url": "https://insights.citeline.com/scrip/digital-technologies/ai/chemomab-scipher-bet-on-taking-ai-powered-precision-medicine-into-immunology-ENV3VV7GKNFXZMOPIYN5SMMB6I/", "source_name": "Scrip", "published_at": "2026-07-08T20:40:18", "published_display": "08 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) M&A announcement Summary", "summary": "Chemomab Therapeutics announced a merger with Scipher, combining AI-powered precision medicine with Chemomab's anti-CCL24 antibody to target rheumatoid arthritis. The all-stock transaction will result in Chemomab shareholders owning approximately 32% of the combined company, with", "url": "https://quartr.com/events/chemomab-therapeutics-ltd-cmmb-m-a-announcement_F6V0bb8M", "source_name": "Quartr", "published_at": "2026-07-08T18:40:18", "published_display": "08 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab and Scipher Medicine agree biotechnology merger", "summary": "Chemomab Therapeutics and Scipher Medicine have announced a stock-based merger, forming Scipher Medicine Corporation, which will focus on advancing nebokitug, an anti-CCL24 antibody, into an AI-guided Phase 2 rheumatoid arthritis trial. The combined company is valued at approxima", "url": "https://grafa.com/en/news/united-states/chemomab-scipher-medicine-merger-nebokitug-rheumatoid-arthritis", "source_name": "grafa.com", "published_at": "2026-07-08T16:40:18", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB Stock Surges As Traders Target Biotech Momentum", "summary": "Shares of Chemomab Therapeutics Ltd. (CMMB) have recently seen significant price action, surging from around $1.50 to the high $2s, demonstrating classic low-float breakout behavior despite recent clinical trial uncertainty. The company's strong cash position relative to liabilit", "url": "https://www.timothysykes.com/news/chemomab-therapeutics-ltd-cmmb-news-2026_07_08/", "source_name": "www.timothysykes.com", "published_at": "2026-07-08T13:40:18", "published_display": "08 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scipher Medicine Corporation entered into an Agreement and Plan of Merger to acquire Chemomab Therapeutics Ltd. with an enterprise value of approximately $100 million in a reverse merger transaction.", "summary": "Scipher Medicine Corporation has formally agreed to acquire Chemomab Therapeutics Ltd. in a reverse merger transaction with an enterprise value of approximately $100 million. The combined entity is valued at $150 million and will be named Scipher Medicine Corporation, trading und", "url": "https://www.marketscreener.com/news/scipher-medicine-corporation-entered-into-an-agreement-and-plan-of-merger-to-acquire-chemomab-therap-ce7f5ed9d188f720?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T13:39:24", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab and Scipher Medicine to merge in $150M deal By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQalJwS25KamtzOVJjaVRMSjhyZlE5cHZvNGxKaHJmQ3VKSTRUYWQxOXB4blFNRXM4Mm93dDdGdjVzVHlEdE1RdVBEQUg1aGYzVTAxZE0zSWduMTYwbVBBSUtqbTQ1U2NRMHdVSi1KdVozcjhadjJxUVZKVTFQVkxzd200ekRiVzRYSjNIbVFydUZrVkk5WGxHeUJwTVV5ajZwWDMyb2NpLXl6elpFSGNEeGdR?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-08T11:48:05+00:00", "published_display": "08 Jul 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab and Scipher Medicine to merge in $150M deal", "summary": "Chemomab Therapeutics and Scipher Medicine Corporation have announced an all-stock merger valued at $150 million, with Chemomab equity holders owning 32% and Scipher 68% of the combined company, which will operate as Scipher Medicine Corporation and trade on Nasdaq as SCIP. The d", "url": "https://www.investing.com/news/company-news/chemomab-and-scipher-medicine-to-merge-in-150m-deal-93CH-4781411", "source_name": "Investing.com", "published_at": "2026-07-08T12:34:45", "published_display": "08 Jul 2026 12:34", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis", "summary": "Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement to combine companies and advance nebokitug, a first-in-class anti-CCL24 antibody, into a precision medicine Phase 2 trial for rheumatoid arthritis. The combined entity, to be named Scipher Med", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323986/0/en/chemomab-therapeutics-and-precision-medicine-pioneer-scipher-medicine-announce-merger-agreement-to-advance-nebokitug-in-an-ai-powered-phase-2-trial-in-rheumatoid-arthritis.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:40:18", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab (CMMB) and Scipher plan merger with $30M financing and CVRs", "summary": "Chemomab Therapeutics and Scipher Medicine announced a definitive merger agreement, creating a new Nasdaq-listed U.S. parent company focused on advancing nebokitug for rheumatoid arthritis (RA) into an AI-enabled Phase 2 trial. The deal involves a $30 million PIPE financing and c", "url": "https://www.stocktitan.net/sec-filings/CMMB/6-k-chemomab-therapeutics-ltd-current-report-foreign-issuer-6909211c1a08.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:11:45", "published_display": "08 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics and Precision Medicine Pioneer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AJBVV95cUxQRGZXX2pvcHJNdjROSVBJUG4xSTZXbmM4N3ZmVGdaWVRvMHVfYmc2VjNxS1B3ZkdfZU04elBtT3VTRC1HZmktclN0SktacFc3dFg2UGh2UWxFT21nVFlqOTU2QkJXaFRBSU1KcFNkLW5ERnVIUUFwQlgtb2RNMElraFJaMzFTTzZDVk5fWF90cDQ0ZVQ0QTRMTWN6eG5RSGw2WmphTTR1QmRKNURJV0kxem9XMmE5M2hMVGZwRWRqRE1yX0NoVWVZS05UQV9JaWxTN29UMlBkaDY5ZWhOUnhEX0sxUkdnek5vWFJQd0c2MlRFZko0U1FEODk0NFZFbTJDa29xb1ZscmZnYWNiY1ktRmVMdGVBcXpQZkpUX0hKdzFocDJBS3RZTEdlQ3Vta3Vscy1BMWJfYWdIRGxvOEg1ZXhFMmd6U3F6NTN0VG5PR3RiZEIxTFdIWEtQY1VJLXdW?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQTWpDYU1LTHlPY083Y1RPX1VQbVZfSGo0OGNhZW5xQk90XzhIeXZBRkpjMFpxWFlsN2d6SUVyeW44aEx1VWZuU2hWWUx1WFdicE5Oa1pmdlVBTDBlekQ1aXdKcnVfNmtwMGE0OGNiTmNMQW9MWDA2LUE2bkF6WGVMSjZlLVBZY0lDZkRMaEY4ZVVJdkNGSVd0eEZGaC14d3NoZ2labjZ6bGpPRW01dFlrSlZFTWNfUVJ6V0ZQNVJic1E2LURrZVNDRE1aWjM4Tk9Oem5HOGRUcENQQlg5WXpFU21sbVlMTWxzLWpWVjRWNy1yLXR2YXd3?oc=5", "source_name": "Moomoo", "published_at": "2026-07-07T21:47:13+00:00", "published_display": "07 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Volatility & Greeks", "summary": "This article provides a detailed financial overview of Chemomab Therapeutics Ltd ADR (CMMB), including its volatility, key financial metrics, stock performance, and insider/institutional ownership. It highlights the company's market capitalization, sales, earnings per share, and ", "url": "https://finviz.com/stock?t=CMMB&ta=1&p=m&ty=ocv&b=1&e=2026-07-04", "source_name": "Finviz", "published_at": "2026-07-05T00:40:35", "published_display": "05 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Earnings", "summary": "This page provides a detailed financial overview of Chemomab Therapeutics Ltd ADR (CMMB), including its latest stock performance, market capitalization, income statements, key financial ratios, and analyst recommendations. The data indicates significant recent stock volatility an", "url": "https://finviz.com/quote?t=CMMB&ty=ea&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T17:09:41", "published_display": "04 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Short Interest", "summary": "This article provides detailed financial data and performance metrics for Chemomab Therapeutics Ltd ADR (CMMB), including its short interest, market capitalization, income, sales, and employee count. It also lists various financial ratios, insider ownership, institutional ownersh", "url": "https://finviz.com/stock?t=CMMB&ta=1&p=m&ty=si&b=1", "source_name": "Finviz", "published_at": "2026-07-04T12:09:41", "published_display": "04 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Chemomab Therapeutics Ltd ADR (CMMB). It details the company's last close price, various financial ratios, performance metrics, and insider/institutional ownership percentages. Key financial figures", "url": "https://finviz.com/stock?t=CMMB&ty=lf&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T15:39:55", "published_display": "03 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB - Chemomab Therapeutics Ltd ADR Options", "summary": "This article provides a detailed financial overview of Chemomab Therapeutics Ltd. (CMMB), an ADR-listed biotechnology company. It covers key financial metrics, stock performance data, insider and institutional ownership, and analyst recommendations. The company's stock closed at ", "url": "https://finviz.com/stock?t=CMMB&p=d&b=1&ty=oc", "source_name": "Finviz", "published_at": "2026-07-03T11:39:55", "published_display": "03 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "11 Health Care Stocks Moving In Thursday's Intraday Session", "summary": "This article lists several healthcare stocks that experienced significant price movements during Thursday's intraday trading session. It highlights both gainers, such as Chemomab Therapeutics and Liminatus Pharma, and decliners, including Elicio Therapeutics and Profusa, detailin", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60253293/11-health-care-stocks-moving-thursday-s-intraday-session", "source_name": "Benzinga", "published_at": "2026-07-02T17:09:35", "published_display": "02 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the forecast and price target for Chemomab Therapeutics Ltd. (CMMB) on the Nasdaq Stock Market. One analyst currently offers a 1-year price forecast, with a price target of 5.00, although maximum and minimum estimates are not provided. The article also touch", "url": "https://www.tradingview.com/symbols/NASDAQ-CMMB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T02:39:34", "published_display": "29 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Edges Higher as Stock Holds Key Support - Pre-Earnings Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNc2JTbWwtRXlXbnQtMW5YcVFhbHNleHcySkNXaWJIbWRDcE5IZFhLdERZeW9WM0p3bEtMcnhGaGZ2TXJEd0lsM0JqQ3dPU3A2a1d0SDhYNDBPYVlBRW9kb1hWczM4MjFaa2NuaEdBYnBmY1VCZlF6VlIxVG1scUdsTGRZenJpZTF6dDVVYm5YWnR3MUJQdTd4YXJDLUg2NVMzZUVWekp5RQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-28T23:48:46+00:00", "published_display": "28 Jun 2026 23:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Chemomab Therapeutics Ltd. \u2013 NASDAQ:CMMB", "summary": "The article provides the \"Enterprise value to revenue forward\" for Chemomab Therapeutics Ltd. (NASDAQ: CMMB). It is presented on the TradingView platform, which offers financial data, charting tools, and community features for various markets including stocks, ETFs, and cryptocur", "url": "https://www.tradingview.com/symbols/NASDAQ-CMMB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:10:18", "published_display": "28 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Chemomab Therapeutics Ltd. Sponsored ADR \u2013 MUN:2QV", "summary": "This article provides financial information for Chemomab Therapeutics Ltd. Sponsored ADR (MUN:2QV), specifically focusing on its forward price-to-earnings ratio. It indicates that the current market for this stock is closed and no trades have occurred. The data is sourced from IC", "url": "https://www.tradingview.com/symbols/MUN-2QV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:18", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQRGFodkhobHN4MGdlVVpEQXFSbGlFZE5hRndHcTFadE53TkRZdC1FVmpzLVdhdmhzWmlZQnVieGczUVdXenZyWWdvU0YwcUhReWFGcmtBNXh3QllHaW5XUnFBcHlGTC1RU1NqVEhBTERjY1NaRk5zRU1rMGFzVks1LUx6WWx2SVh1dnpjTjlLVy00Ri00emZFVWpOc0dQQjNHaGUya2Z6Sk1nNWRKQmExTE9pWlVMQVlRdV82bk9SWWNmejBhRnU3WnFEajdwaTJIeDlLRmdFejZxakxEQXp2UXFVazBqZTRsMWliNkdLWGljZ2Y4SUthb0Ryc3BLTVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chemomab Therapeutics (CMMB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1YVEFWNUktd1dVTHJ5SGpVTGp0VFdtelh4WTBQeXlwMVh2REpmOGJMZlAtYUdrbWo0czVHNGpMRERrR3lxSzZCUm0zVDFla2ZSaFV3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:23:46+00:00", "published_display": "24 Apr 2025 23:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMMB: Chemomab Therapeutics Ltd - ADR Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFBVLUJjenRwT2hHMUlNNkV0YWZsNjBfZlF3WkJIZUdGM245YVRPQ3h4TlM1Nk84X0FsN3hXSnpnM3RKTTd1bC1NeUFn?oc=5", "source_name": "Stocktwits", "published_at": "2021-04-04T01:51:28+00:00", "published_display": "04 Apr 2021 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 82, "total_relevant": 45, "sentiment_summary": {"positive": 19, "negative": 1, "neutral": 25, "score": 60, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 74, "events": [{"event": "earnings", "label": "Earnings", "weight": 9.76, "count": 20}, {"event": "general", "label": "Market update", "weight": 5.85, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 5.5, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 1.56, "latest_week": "2026-07-17", "one_week_move": -10.3, "four_week_move": 2.6, "twelve_week_move": -3.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.309308, "market_dynamics_buy_signal": false, "relative_strength": -39.399518, "fair_value_gap": -59.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 37.3044, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.3% over one week, +2.6% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Quartr", "count": 6}, {"label": "Market source", "count": 6}, {"label": "Finviz", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "dars.gov.et", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 20}, {"label": "Deals and strategy", "count": 10}, {"label": "Market update", "count": 10}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-10.3% over one week, +2.6% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Chemomab Therapeutics (CMMB) Q3 2025 earnings summary"}], "updated_at": "2026-07-23T03:35:33.248914+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}